TY - JOUR
T1 - Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis
AU - Canbay, Ali
AU - Guicciardi, Maria Eugenia
AU - Higuchi, Hajime
AU - Feldstein, Ariel
AU - Bronk, Steven F.
AU - Rydzewski, Robert
AU - Taniai, Makiko
AU - Gores, Gregory J.
PY - 2003/7
Y1 - 2003/7
N2 - Although a lysosomal, cathepsin B-dependent (Ctsb-dependent) pathway of apoptosis has been described, the contribution of this pathway to tissue damage remains unclear. Our aim was to ascertain if Ctsb inactivation attenuates liver injury, inflammation, and fibrogenesis after bile duct ligation (BDL). In 3-day BDL mice, hepatocyte apoptosis, mitochondrial cytochrome c release, and serum alanine aminotransferase (ALT) values were reduced in Ctsb-/- versus Ctsb+/+ animals. Likewise, R-3032 (a Ctsb inhibitor) also reduced these parameters in BDL WT mice. Both genetic and pharmacologic inhibition of Ctsb in the BDL mouse reduced (a) hepatic inflammation, as assessed by transcripts for CXC chemokines and neutrophil infiltration, and (b) fibrogenesis, as assessed by transcripts for stellate cell activation and sirius red staining for hepatic collagen deposition. These differences could not be ascribed to alterations in cholestasis. These findings support a prominent role for the lysosomal pathway of apoptosis in tissue injury and link apoptosis to inflammation and fibrogenesis. Ctsb inhibition may be therapeutic in liver diseases.
AB - Although a lysosomal, cathepsin B-dependent (Ctsb-dependent) pathway of apoptosis has been described, the contribution of this pathway to tissue damage remains unclear. Our aim was to ascertain if Ctsb inactivation attenuates liver injury, inflammation, and fibrogenesis after bile duct ligation (BDL). In 3-day BDL mice, hepatocyte apoptosis, mitochondrial cytochrome c release, and serum alanine aminotransferase (ALT) values were reduced in Ctsb-/- versus Ctsb+/+ animals. Likewise, R-3032 (a Ctsb inhibitor) also reduced these parameters in BDL WT mice. Both genetic and pharmacologic inhibition of Ctsb in the BDL mouse reduced (a) hepatic inflammation, as assessed by transcripts for CXC chemokines and neutrophil infiltration, and (b) fibrogenesis, as assessed by transcripts for stellate cell activation and sirius red staining for hepatic collagen deposition. These differences could not be ascribed to alterations in cholestasis. These findings support a prominent role for the lysosomal pathway of apoptosis in tissue injury and link apoptosis to inflammation and fibrogenesis. Ctsb inhibition may be therapeutic in liver diseases.
UR - http://www.scopus.com/inward/record.url?scp=0042744006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042744006&partnerID=8YFLogxK
U2 - 10.1172/JCI200317740
DO - 10.1172/JCI200317740
M3 - Article
C2 - 12865404
AN - SCOPUS:0042744006
SN - 0021-9738
VL - 112
SP - 152
EP - 159
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 2
ER -